Which has better earnings & valuation, RDCM or PHUN?

Radcom has higher revenue and earnings than Phunware. Phunware is trading at a lower price-to-earnings ratio than Radcom, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Radcom $67.59M 2.45 $11.99M $0.42 23.60 Phunware $2.75M 15.10 -$11.40M -$0.65 N/A

Is RDCM or PHUN more profitable?

Radcom has a net margin of 10.47% compared to Phunware's net margin of -471.72%. Radcom's return on equity of 6.51% beat Phunware's return on equity. Company Net Margins Return on Equity Return on Assets Radcom 10.47% 6.51% 5.17% Phunware -471.72% -13.79% -12.37%

Does the media refer more to RDCM or PHUN?

In the previous week, Radcom had 2 more articles in the media than Phunware. MarketBeat recorded 4 mentions for Radcom and 2 mentions for Phunware. Radcom's average media sentiment score of 0.94 beat Phunware's score of 0.76 indicating that Radcom is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Radcom 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Phunware 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend PHUN or ZSQR?

Phunware presently has a consensus price target of $2.00, suggesting a potential downside of 1.48%. Given Phunware's stronger consensus rating and higher probable upside, equities research analysts clearly believe Phunware is more favorable than Coeptis Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Phunware 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Coeptis Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer PHUN or ZSQR?

In the previous week, Coeptis Therapeutics had 2 more articles in the media than Phunware. MarketBeat recorded 4 mentions for Coeptis Therapeutics and 2 mentions for Phunware. Coeptis Therapeutics' average media sentiment score of 0.83 beat Phunware's score of 0.76 indicating that Coeptis Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Phunware 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Coeptis Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, EGAN or PHUN?

eGain has higher revenue and earnings than Phunware. Phunware is trading at a lower price-to-earnings ratio than eGain, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio eGain $91.14M 1.58 $8.88M $0.32 16.44 Phunware $2.75M 15.10 -$11.40M -$0.65 N/A

Is EGAN or PHUN more profitable?

eGain has a net margin of 9.74% compared to Phunware's net margin of -471.72%. eGain's return on equity of 11.63% beat Phunware's return on equity. Company Net Margins Return on Equity Return on Assets eGain 9.74% 11.63% 7.12% Phunware -471.72% -13.79% -12.37%

Does the media refer more to EGAN or PHUN?

In the previous week, eGain had 5 more articles in the media than Phunware. MarketBeat recorded 7 mentions for eGain and 2 mentions for Phunware. Phunware's average media sentiment score of 0.76 beat eGain's score of 0.36 indicating that Phunware is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment eGain 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Phunware 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend RAAS or PHUN?

Phunware has a consensus price target of $2.00, indicating a potential downside of 1.48%. Given Phunware's stronger consensus rating and higher probable upside, analysts plainly believe Phunware is more favorable than Cloopen Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cloopen Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Phunware 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has stronger valuation and earnings, RAAS or PHUN?

Phunware has lower revenue, but higher earnings than Cloopen Group. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cloopen Group $1.01B 0.13 -$34.23M N/A N/A Phunware $2.75M 15.10 -$11.40M -$0.65 N/A

Do analysts rate PHUN or TRAK?

Phunware currently has a consensus target price of $2.00, suggesting a potential downside of 1.48%. Given Phunware's higher probable upside, research analysts plainly believe Phunware is more favorable than ReposiTrak. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Phunware 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 ReposiTrak 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger earnings and valuation, PHUN or TRAK?

ReposiTrak has higher revenue and earnings than Phunware. Phunware is trading at a lower price-to-earnings ratio than ReposiTrak, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Phunware $2.75M 15.10 -$11.40M -$0.65 N/A ReposiTrak $22.61M 6.43 $6.98M $0.37 21.62

Is PHUN or TRAK more profitable?

ReposiTrak has a net margin of 30.75% compared to Phunware's net margin of -471.72%. ReposiTrak's return on equity of 14.44% beat Phunware's return on equity. Company Net Margins Return on Equity Return on Assets Phunware -471.72% -13.79% -12.37% ReposiTrak 30.75% 14.44% 12.85%

Does the media favor PHUN or TRAK?

In the previous week, ReposiTrak had 1 more articles in the media than Phunware. MarketBeat recorded 3 mentions for ReposiTrak and 2 mentions for Phunware. Phunware's average media sentiment score of 0.76 beat ReposiTrak's score of 0.56 indicating that Phunware is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Phunware 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive ReposiTrak 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Phunware (PHUN) Competitors

$2.03 +0.01 (+0.50%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$2.03 +0.00 (+0.20%)

As of 09/11/2026 07:56 PM Eastern

Compare

PHUN vs. RDCM, ZSQR, EGAN, RAAS, and TRAK

Should you buy Phunware stock or one of its competitors? Phunware's main competitors and comparable companies include Radcom (RDCM), Coeptis Therapeutics (ZSQR), eGain (EGAN), Cloopen Group (RAAS), and ReposiTrak (TRAK). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "application software" industry.

How does Phunware compare to Radcom?

Radcom (NASDAQ:RDCM) and Phunware (NASDAQ:PHUN) are both small-cap technology companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, media sentiment, institutional ownership, earnings and risk.

Radcom has a beta of 0.74, indicating that its share price is 26% less volatile than the broader market. Comparatively, Phunware has a beta of 2.61, indicating that its share price is 161% more volatile than the broader market.

In the previous week, Radcom had 2 more articles in the media than Phunware. MarketBeat recorded 4 mentions for Radcom and 2 mentions for Phunware. Radcom's average media sentiment score of 0.94 beat Phunware's score of 0.76 indicating that Radcom is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Radcom	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Phunware	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Radcom has a net margin of 10.47% compared to Phunware's net margin of -471.72%. Radcom's return on equity of 6.51% beat Phunware's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Radcom	10.47%	6.51%	5.17%
Phunware	-471.72%	-13.79%	-12.37%

Radcom has higher revenue and earnings than Phunware. Phunware is trading at a lower price-to-earnings ratio than Radcom, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Radcom	$67.59M	2.45	$11.99M	$0.42	23.60
Phunware	$2.75M	15.10	-$11.40M	-$0.65	N/A

Radcom presently has a consensus price target of $14.00, suggesting a potential upside of 41.27%. Phunware has a consensus price target of $2.00, suggesting a potential downside of 1.48%. Given Radcom's stronger consensus rating and higher possible upside, research analysts plainly believe Radcom is more favorable than Phunware.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Radcom	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Phunware	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

48.3% of Radcom shares are owned by institutional investors. Comparatively, 7.6% of Phunware shares are owned by institutional investors. 69.0% of Radcom shares are owned by company insiders. Comparatively, 0.2% of Phunware shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Radcom beats Phunware on 14 of the 16 factors compared between the two stocks.

How does Phunware compare to Coeptis Therapeutics?

Phunware (NASDAQ:PHUN) and Coeptis Therapeutics (NASDAQ:ZSQR) are both small-cap technology companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, earnings, media sentiment, valuation, risk and dividends.

In the previous week, Coeptis Therapeutics had 2 more articles in the media than Phunware. MarketBeat recorded 4 mentions for Coeptis Therapeutics and 2 mentions for Phunware. Coeptis Therapeutics' average media sentiment score of 0.83 beat Phunware's score of 0.76 indicating that Coeptis Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Phunware	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Coeptis Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Phunware has higher revenue and earnings than Coeptis Therapeutics. Phunware is trading at a lower price-to-earnings ratio than Coeptis Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phunware	$2.75M	15.10	-$11.40M	-$0.65	N/A
Coeptis Therapeutics	$1.36M	119.64	-$11.92M	-$1.63	N/A

Phunware has a net margin of -471.72% compared to Coeptis Therapeutics' net margin of -773.72%. Phunware's return on equity of -13.79% beat Coeptis Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phunware	-471.72%	-13.79%	-12.37%
Coeptis Therapeutics	-773.72%	-49.45%	-46.88%

Phunware has a beta of 2.61, indicating that its stock price is 161% more volatile than the broader market. Comparatively, Coeptis Therapeutics has a beta of -0.25, indicating that its stock price is 125% less volatile than the broader market.

7.6% of Phunware shares are owned by institutional investors. Comparatively, 13.9% of Coeptis Therapeutics shares are owned by institutional investors. 0.2% of Phunware shares are owned by insiders. Comparatively, 24.3% of Coeptis Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Phunware presently has a consensus price target of $2.00, suggesting a potential downside of 1.48%. Given Phunware's stronger consensus rating and higher probable upside, equities research analysts clearly believe Phunware is more favorable than Coeptis Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phunware	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Coeptis Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Phunware beats Coeptis Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Phunware compare to eGain?

eGain (NASDAQ:EGAN) and Phunware (NASDAQ:PHUN) are both small-cap technology companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, media sentiment, institutional ownership and analyst recommendations.

eGain has a beta of 0.83, suggesting that its share price is 17% less volatile than the broader market. Comparatively, Phunware has a beta of 2.61, suggesting that its share price is 161% more volatile than the broader market.

eGain currently has a consensus target price of $6.50, indicating a potential upside of 23.57%. Phunware has a consensus target price of $2.00, indicating a potential downside of 1.48%. Given eGain's stronger consensus rating and higher possible upside, research analysts plainly believe eGain is more favorable than Phunware.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
eGain	0 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Phunware	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

53.9% of eGain shares are owned by institutional investors. Comparatively, 7.6% of Phunware shares are owned by institutional investors. 38.7% of eGain shares are owned by insiders. Comparatively, 0.2% of Phunware shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, eGain had 5 more articles in the media than Phunware. MarketBeat recorded 7 mentions for eGain and 2 mentions for Phunware. Phunware's average media sentiment score of 0.76 beat eGain's score of 0.36 indicating that Phunware is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
eGain	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Phunware	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

eGain has higher revenue and earnings than Phunware. Phunware is trading at a lower price-to-earnings ratio than eGain, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
eGain	$91.14M	1.58	$8.88M	$0.32	16.44
Phunware	$2.75M	15.10	-$11.40M	-$0.65	N/A

eGain has a net margin of 9.74% compared to Phunware's net margin of -471.72%. eGain's return on equity of 11.63% beat Phunware's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
eGain	9.74%	11.63%	7.12%
Phunware	-471.72%	-13.79%	-12.37%

Summary

eGain beats Phunware on 12 of the 15 factors compared between the two stocks.

How does Phunware compare to Cloopen Group?

Cloopen Group (NYSE:RAAS) and Phunware (NASDAQ:PHUN) are both small-cap technology companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, media sentiment, profitability, risk and earnings.

Cloopen Group has a beta of 0.54, meaning that its stock price is 46% less volatile than the broader market. Comparatively, Phunware has a beta of 2.61, meaning that its stock price is 161% more volatile than the broader market.

In the previous week, Phunware had 2 more articles in the media than Cloopen Group. MarketBeat recorded 2 mentions for Phunware and 0 mentions for Cloopen Group. Phunware's average media sentiment score of 0.76 beat Cloopen Group's score of 0.00 indicating that Phunware is being referred to more favorably in the news media.

Company	Overall Sentiment
Cloopen Group	Neutral
Phunware	Positive

Phunware has lower revenue, but higher earnings than Cloopen Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cloopen Group	$1.01B	0.13	-$34.23M	N/A	N/A
Phunware	$2.75M	15.10	-$11.40M	-$0.65	N/A

Phunware has a consensus price target of $2.00, indicating a potential downside of 1.48%. Given Phunware's stronger consensus rating and higher probable upside, analysts plainly believe Phunware is more favorable than Cloopen Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cloopen Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Phunware	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Cloopen Group has a net margin of 0.00% compared to Phunware's net margin of -471.72%. Cloopen Group's return on equity of 0.00% beat Phunware's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cloopen Group	N/A	N/A	N/A
Phunware	-471.72%	-13.79%	-12.37%

7.6% of Phunware shares are held by institutional investors. 9.8% of Cloopen Group shares are held by company insiders. Comparatively, 0.2% of Phunware shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Phunware beats Cloopen Group on 8 of the 13 factors compared between the two stocks.

How does Phunware compare to ReposiTrak?

Phunware (NASDAQ:PHUN) and ReposiTrak (NYSE:TRAK) are both small-cap technology companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation, institutional ownership and media sentiment.

Phunware has a beta of 2.61, meaning that its share price is 161% more volatile than the broader market. Comparatively, ReposiTrak has a beta of 0.83, meaning that its share price is 17% less volatile than the broader market.

ReposiTrak has a net margin of 30.75% compared to Phunware's net margin of -471.72%. ReposiTrak's return on equity of 14.44% beat Phunware's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phunware	-471.72%	-13.79%	-12.37%
ReposiTrak	30.75%	14.44%	12.85%

Phunware currently has a consensus target price of $2.00, suggesting a potential downside of 1.48%. Given Phunware's higher probable upside, research analysts plainly believe Phunware is more favorable than ReposiTrak.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phunware	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
ReposiTrak	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

7.6% of Phunware shares are held by institutional investors. Comparatively, 27.4% of ReposiTrak shares are held by institutional investors. 0.2% of Phunware shares are held by insiders. Comparatively, 41.0% of ReposiTrak shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, ReposiTrak had 1 more articles in the media than Phunware. MarketBeat recorded 3 mentions for ReposiTrak and 2 mentions for Phunware. Phunware's average media sentiment score of 0.76 beat ReposiTrak's score of 0.56 indicating that Phunware is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Phunware	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
ReposiTrak	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ReposiTrak has higher revenue and earnings than Phunware. Phunware is trading at a lower price-to-earnings ratio than ReposiTrak, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phunware	$2.75M	15.10	-$11.40M	-$0.65	N/A
ReposiTrak	$22.61M	6.43	$6.98M	$0.37	21.62

Summary

ReposiTrak beats Phunware on 11 of the 15 factors compared between the two stocks.

Get Phunware News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PHUN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PHUN vs. The Competition

Export

Metric	Phunware	Software Industry	Technology Sector	NASDAQ Exchange
Market Cap	$41.34M	$15.42B	$29.64B	$12.72B
Dividend Yield	N/A	3.43%	2.74%	11.15%
P/E Ratio	-3.12	138.41	76.55	25.29
Price / Sales	15.10	1,286.68	588.63	98.94
Price / Cash	N/A	45.12	47.50	51.44
Price / Book	0.43	8.34	7.70	6.20
Net Income	-$11.40M	$434.47M	$704.99M	$358.50M
7 Day Performance	-2.40%	-2.04%	-1.08%	-2.35%
1 Month Performance	-3.33%	-1.09%	-3.65%	-2.77%
1 Year Performance	-25.64%	-0.19%	180.35%	7.63%

Phunware Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PHUN Phunware	0.5502 of 5 stars	$2.03 +0.5%	$2.00 -1.5%	-24.5%	$41.34M	$2.75M	N/A	120	High Trading Volume
RDCM Radcom	3.4026 of 5 stars	$9.84 -1.9%	$14.00 +42.3%	-31.0%	$165.32M	$71.49M	23.51	280	News Coverage Analyst Downgrade
ZSQR Coeptis Therapeutics	0.4214 of 5 stars	$3.01 +2.0%	N/A	-75.3%	$159.53M	$1.36M	N/A	2	News Coverage Gap Up
EGAN eGain	2.2184 of 5 stars	$5.31 -9.1%	$8.75 +64.9%	-35.0%	$145.07M	$91.14M	16.52	690	Analyst Forecast
RAAS Cloopen Group	N/A	$2.48 +1.2%	N/A	+83.0%	$141.43M	$76.61M	N/A	1,008	Gap Down High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PHUN) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Phunware (PHUN) Competitors